Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Future Capital AG is a venture capital firm based in Hessen, Germany, established in the late 1990s. The organization focuses on investments in the life sciences and chemical sectors, particularly in early-stage and startup companies. With a fund size of approximately $64 million, Future Capital AG has a long-standing presence in the venture capital space, having been founded around 1999. The firm has historically supported companies in healthcare and biotechnology, emphasizing the importance of digital health solutions and innovative chemistry applications.
Despite its active role in the past, recent reports indicate that Future Capital AG has ceased making new investments since 2020. The firm was co-financed 50% by Land Hessen and 50% by Sanofi-Aventis Deutschland GmbH, reflecting a strong public-private partnership aimed at fostering innovation in the life sciences sector. Although the firm remains legally active, its current status suggests it is likely defunct in terms of new investments.
Future Capital AG primarily invests in the life sciences and chemical industries, targeting early-stage and startup companies. The firm emphasizes digital health solutions and innovative chemistry applications as key areas of interest. Its investment strategy is designed to support companies that leverage technology to address medical challenges and enhance healthcare delivery.
The organization has historically focused on various sectors within life sciences, including biotechnology, healthcare, and digital health. Future Capital AG's investment thesis centers on providing capital, industry expertise, and a robust network to help startups navigate the complexities of these sectors. The firm aims to back companies that are developing innovative solutions in healthcare, particularly those utilizing digital products to solve medical problems.
Future Capital AG's notable portfolio includes several companies that exemplify its focus on life sciences and healthcare:
These companies reflect Future Capital AG's commitment to supporting innovative solutions in healthcare and biotechnology, although the firm's current investment activity is uncertain.
Christian Leikert — CEO / Vorstand. Leikert has a background at Creathor Ventures and is currently listed as CEO of Future Capital AG. His expertise lies in venture capital and investment management.
Ingmar Jung — Vorstandsvorsitzender / Vorstand. Jung is a current representative of Future Capital AG, although prior roles and specific investment focus are not disclosed.
Dr. Klaus Menken — Vorstand. Menken is also a current representative of the firm, with no additional details available regarding his background or investment focus.
Mathias Samson — Vorstand. Samson serves as a current representative of Future Capital AG, but specific details about his prior experience and investment focus are not provided.
Future Capital AG has not made any new investments since 2020, as confirmed by multiple sources, including the Hessen government participation report. This cessation of new investments indicates a significant shift in the firm's operational strategy.
Recent reports have mentioned Aircode as a potential investment, but this status remains uncertain due to conflicting information regarding the firm's current investment activity.
As of now, Future Capital AG appears to be in a state of inactivity concerning new funding opportunities, which may impact its portfolio companies and their growth trajectories.
What are Future Capital AG's investment criteria?
Future Capital AG focuses on early-stage and startup companies in the life sciences and chemical sectors, particularly those involved in digital health and innovative chemistry applications. The firm seeks to invest in companies that demonstrate potential for significant growth and innovation.
How can I pitch to Future Capital AG?
Currently, Future Capital AG is not accepting new investments, as they have ceased making new investments since 2020. Therefore, there is no active pitch process available.
What makes Future Capital AG different from other investors?
Future Capital AG distinguishes itself through its strong focus on the life sciences and chemical sectors, backed by a significant public-private partnership. The firm provides not only financial support but also access to a robust network and industry expertise, which can be invaluable for startups navigating complex markets.
What is the geographic focus of Future Capital AG?
The firm primarily focuses on investments within Hessen, Germany, and has a broader interest in the European market. This geographic focus allows them to leverage local industry knowledge and connections.
What is the fund size of Future Capital AG?
Future Capital AG manages a fund size of approximately $64 million, which has been allocated to support early-stage investments in the life sciences and chemical sectors.
What is the typical check size for investments?
Specific check sizes have not been disclosed, but the firm targets early-stage investments, which typically range from seed funding to initial rounds for startups.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.